Voclosporin + Placebo Oral Capsule
Phase 3Terminated 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Adolescent Lupus Nephritis
Conditions
Adolescent Lupus Nephritis, Pediatric Lupus Nephritis
Trial Timeline
Oct 10, 2023 → Jul 3, 2025
NCT ID
NCT05288855About Voclosporin + Placebo Oral Capsule
Voclosporin + Placebo Oral Capsule is a phase 3 stage product being developed by Aurinia Pharmaceuticals for Adolescent Lupus Nephritis. The current trial status is terminated. This product is registered under clinical trial identifier NCT05288855. Target conditions include Adolescent Lupus Nephritis, Pediatric Lupus Nephritis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05288855 | Phase 3 | Terminated |
| NCT03597464 | Phase 3 | Completed |
| NCT03021499 | Phase 3 | Completed |
Competing Products
8 competing products in Adolescent Lupus Nephritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lorcaserin | Eisai | Phase 1 | 33 |
| RSS0343 Tabella | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Exenatide Once Weekly + Placebo | AstraZeneca | Phase 3 | 77 |
| Placebo + IBI362 | Innovent Biologics | Phase 3 | 76 |
| IBI362 + IBI362 placebo | Innovent Biologics | Phase 1 | 32 |
| Antipsychotics, mood stabilizers, etc. | Brain Biotech | Pre-clinical | 15 |
| voclosporin | Aurinia Pharmaceuticals | Phase 3 | 72 |
| rizatriptan benzoate | Organon | Phase 3 | 72 |